dual-payload Her2 ADC / MediLink - LARVOL DELTA

An innovative dual-payload ADC combining topoisomerase 1 inhibitor and a tubulin inhibitor efficiently overcomes drug resistance (AACR 2025) - "ADC characterization showed good stability, homogeneity and precise DAR values for the conjugation of both payload-linkers to Trastuzumab. In summary, we developed dual-payload ADCs with intention for resolving topo1 inhibitor induced tumor resistance issues. The dual-payload Her2 ADC demonstrated potent in vitro and in vivo anti-tumor activities, showing the potential to overcome the multidrug resistant mechanism and Enhertu resistance."

Oncology • ABCB1 • ABCG2 • HER-2